Precision Medicine and Pancreatic Cancer

For several decades, cytotoxic chemotherapy was the mainstay of treatment for pancreatic ductal adenocarcinoma (PDAC). Advances in molecular profiling have identified predictive genomic alterations in PDAC —the germline and somatic genome are now routinely interrogated in patients with PDAC because of their therapeutic relevance. The composite role of the epithelial cell compartment and the tumor microenvironment in defining PDAC biology needs further elucidation to deconvolute the spatiotemporal he terogeneity appreciated in this disease. Novel clinical trial approaches leveraging signal seeking, adaptive statistical designs, and master protocols using several candidate drugs that target relevant therapeutic targets are are essential to unlocking the potential of precision medicine in PDAC.
Source: Surgical Oncology Clinics of North America - Category: Surgery Authors: Source Type: research